{"id":257050,"date":"2025-07-28T09:29:54","date_gmt":"2025-07-28T09:29:54","guid":{"rendered":"https:\/\/project.uniurb.it\/vitality\/?p=257050"},"modified":"2025-07-28T14:28:18","modified_gmt":"2025-07-28T14:28:18","slug":"fingerprint-of-the-oxido-reductase-ero1-a-protein-disulfide-bond-producer-and-supporter-of-cancer","status":"publish","type":"post","link":"https:\/\/project.uniurb.it\/vitality\/fingerprint-of-the-oxido-reductase-ero1-a-protein-disulfide-bond-producer-and-supporter-of-cancer\/","title":{"rendered":"Fingerprint of the oxido-reductase ERO1: A protein disulfide bond producer and supporter of cancer"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”2px|||||” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”50px|||||” locked=”off” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”16px” custom_margin=”||60px||false|false” global_colors_info=”{}”]<\/p>\n

Dott.ssa\u00a0<\/span>Ester Zito<\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” locked=”on” global_colors_info=”{}”]<\/p>\n

Abstract<\/h3>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Endoplasmic reticulum oxidoreductin 1 (ERO1) alpha (ERO1A) is an endoplasmic reticulum (ER)-localized protein disulfide oxidoreductase, involved in the disulfide bond formation of proteins. ERO1’s activity in oxidative protein folding is redundant in higher eukaryotes and its loss is well compensated. Although it is dispensable in non-cancer cells, high ERO1 levels are seen with different cancers and predict their malignant phenotype. ERO1 fosters tumor aggressiveness and the response to drug therapy in hypoxic and highly metastatic tumors. It regulates vascular endothelial growth factor (VEGF) levels, oxidative folding and N-glycosylation in hypoxic conditions, boosting tumor fitness and angiogenesis on multiple levels. In addition, ERO1 regulates protein death ligand-1 (PD-L1) on tumors, interfering with the related immune surveillance mechanism, hence acting on the tumors’ response to immune check-point inhibitors (ICI). This all points to inhibition of ERO1 as an effective pharmacological tool, selectively targeting tumors while sparing non-cancer cells from cytotoxicity. The critical discussion here closely examines the molecular basis for ERO1’s involvement in tumors and ERO1 in-hibition strategies for their treatment.<\/span><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||0px|||” locked=”on” global_colors_info=”{}”]<\/p>\n

Keyword<\/h4>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n